Trump admin limits fall COVID-19 boosters to seniors, high-risk groups; FDA calls for more data before broader approval.

Dr. Susan Girois hosted the conversation discussing several topics relating to vaccines, including how they are developed and tested.

Changes are on the way for COVID vaccines after the FDA adjusted the standard of evidence needed to approve shots for the general public.

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

Under a new policy announced Tuesday by the Trump administration, only people age 65 and older and children or young adults ...

The Trump administration said it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending ...

The World Health Organization's member countries have approved an agreement to better prevent, prepare for and respond to ...

Federal officials unveiled a rigorous regulatory approach to future COVID vaccines that could make it harder for many people ...

Dr. Peter Chin Hong, a Bay Area infectious disease expert, discusses the stricter policy from the Food and Drug ...

In the NEJM article, the FDA notes that covid booster uptake has been low in the US, with less than a quarter of people ...

The Food and Drug Administration has outlined new regulations for COVID-19 booster shots, setting stricter approval standards ...